Evidence map›Paper›PMID 40711392›Full record

Trial reportClinical pharmacology in drug development2025

Population Pharmacokinetic and Exposure-Response Analysis of the Cognitive Effects of TAK-071 in Participants With Parkinson Disease and Cognitive Impairment.

Hongxia Jia, Axel Facius, Rachel Jennings, Yaming Hang, Jaya Padmanabhan, Niraj M Shanbhag, Brian T Harel, Arthur Simen, Wei Yin

Abstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongxia JiaQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Axel FaciusthinkQ2 AG, Baar, Switzerland.
Rachel JenningsQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Yaming HangQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Jaya PadmanabhanQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Niraj M ShanbhagQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Brian T HarelQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Arthur SimenQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Wei YinQuantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TAK-071 is a novel muscarinic M

Indexed as

CognitionCognitive DysfunctionParkinson DiseaseAccidental FallsAdministration, OralAdultAgedDose-Response Relationship, DrugFemaleHumansIsoindolesMaleMiddle AgedModels, BiologicalPyrazolesYoung AdultIsoindolesPyrazolesTAK-071cognitive impairmentcorrelation analysisexposure–response analysisParkinson diseasepopulation pharmacokinetic analysis

Identifiers

PMID40711392
PMCPMC12583984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.